Android app Apple app link

PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1

By Yahoo! Finance   |   3 weeks ago
PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1

PepGen Inc. (NASDAQ:PEPG) will cease DMD research due to failed trial results, focusing on DM1 program instead. CEO James McArthur expressed disappointment but highlighted promising prospects in DM1 therapy.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.